Board summary
Key figures
52,399
Registered population
57.6% aged 18–64
22.9%
Aged 65+
ICB 19.0% · England 17.9%
9.6%
Ethnic minority (non-White)
4.9% Asian · England 9.6%
3.9%
In IMD quintile 1
ICB 31.9% · England 21.0%
~1,911
Core20 residents (est.)
Resident basis; registered basis ~2,033 · see page 3
8,243
Hypertension register
+6.27% in 3 yrs · England +5.60%
398
SMI register
10% of Cheshire East (LAD)'s
663
COPD register
Reviews -5.15% in 3 yrs
Forecast to 2030
9,835
Hypertension patients, 2030
+1,592 on today
70.2%
QRISK ≥20% on statins, 2030
+3.09pp over 3 yrs
6.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell behind England.
Asthma reviews fell 6.0% over 2023 to 2025 to 61.2% (England +4.4% to 65.7%), leaving 1,214 register patients unreviewed; a recall audit would test.
Pre-school MMR2 and booster coverage gaps.
In Q1 2025/26, age-5 MMR2 (91.1%) trails MMR1 (96.3%) by 5.2 pp and 4-in-1 is 86.7% against the 95.0% target, possibly reflecting unverified recall.
Heart failure, hypertension and diabetes control exceed England.
Heart failure reviews reach 85.2% (England 78.5%), hypertension treatment to target 70.8% (England 70.3%) and non-frail diabetes HbA1c control 59.7% (England 57.4%).
Population, age and ethnicity
Older adults comprise 22.9% of patients across six practices alongside 20 care homes
Across six practices with 52,399 registered patients, 22.9% (11,972 patients) are aged 65+, above Cheshire East (22.6%), the ICB (19.0%) and England (17.9%). The non-White resident share is 9.6%, with Asian or Asian British residents at 4.9% (LAD 2.4%, ICB 2.8%, England 9.6%), peaking at 7.8% around Handforth Health Centre. White residents comprise 90.4% (LAD 94.4%, ICB 93.0%, England 81.1%). An unverified projection indicates 4.1% list growth to 2030 (LAD 3.4%, ICB 2.3%, England 2.3%). Ethnicity figures reflect Census usual residents rather than GP registrations, while age bands reflect registered lists.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation is low at PCN decile 8.4 but concentrated in two practices
Average IMD decile is 8.4, above Cheshire East (7.1), the ICB (5.2) and England (5.5). Registered Core20 share is 3.9%, below Cheshire East (9.2%), the ICB (31.9%) and England (21.0%). Deprivation is concentrated in two practices: Handforth Health Centre has a 14.4% share (1,496 estimated patients) and Wilmslow Health Centre has 3.2% (537 estimated patients). Resident LSOA estimates identify 1,911 people in deciles 1 and 2, differing from practice-modelled totals (2,033). Outreach should prioritise Handforth Health Centre for concentration and Wilmslow Health Centre for volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
398
SMI register
0.76% recorded prevalence
279
Learning disability register
0.53% recorded prevalence
20
Care homes, 1,247 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
The PCN records 279 learning disability patients (0.5% prevalence; LAD 0.5%, ICB 0.6%, England 0.6%) and 398 severe mental illness patients (0.8%; LAD 0.9%, ICB 1.1%, England 1.0%). Catchments include 20 care homes with 1,247 beds, though beds do not establish resident occupancy. While crude prevalence does not establish unmet need, annual physical health checks support routine monitoring for registered cohorts.
Severe mental illness: physical health checks
SMI blood pressure checks fell 3.4 pp over 2023 to 2025 to 78.0% (England +4.4 pp to 83.4%), while alcohol recording was 71.9% (England 81.8%). Across 398 SMI patients, this is consistent with unverified annual review gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,243
Hypertension register
+6.27%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
+0.47pp
BP control, under 80
≤140/90 · −2.30pp aged 80+
+1,592
More patients by 2030
Forecast 9,835 (17.72%)
Hypertension case-finding and control
Hypertension prevalence is 15.7% (8,243 patients), above England (15.2%) but below Cheshire East (17.3%) and the ICB (16.8%), though crude rates are not age-adjusted. While 90.3% had a recent blood pressure check (England 90.0%) and overall treatment to target is 70.8% (England 70.3%), control in patients aged 80+ fell 2.8% over 2023 to 2025 (England +2.2%) to 79.9% (England 81.2%). This drop could reflect unverified follow-up delays or prescribing differences. Older hypertensive patients trail national control benchmarks, so the PCN should prioritise targeted medication reviews and home blood pressure monitoring for patients aged 80 and over.
Lipids and statins
Statin treatment for diabetes primary prevention is 69.8%, trailing England (73.2%), Cheshire East (71.0%) and the ICB (72.4%). Secondary prevention reaches 83.2% (England 84.4%). Lower primary-prevention statin coverage leaves diabetic patients under-protected, indicating an opportunity to prioritise routine statin initiation audits in diabetes reviews.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 100,423 | £1.90 | £1.71 | £1.86 | £190,804 |
| Cardiovascular (all), 2025 | 127,283 | £4.23 | £4.37 | £3.33 | £538,407 |
In 2026, the PCN prescribed 100,423 lipid-regulating items at £1.90 per item, above England (£1.86), Cheshire East (£1.72) and the ICB (£1.71). Across these items, the PCN spends £4,017 more than at England's unit cost. Higher unit costs on lipid-regulating items suggest an opportunity to review formulary adherence and switch to lower-cost statin options.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.99%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.36%
Asthma prevalence, PCN 3-yr % change
Over 2023 to 2025, asthma annual reviews fell 6.0% to 61.2% (England +4.4% to 65.7%), leaving an estimated 1,214 of 3,131 register patients unreviewed. COPD reviews fell 5.2% to 75.0% across 663 patients (England +2.8% to 76.4%). Asthma prevalence is 6.3% (England 6.6%) and COPD is 1.3% (England 1.9%). Slower review delivery, alongside second-hand smoking recording at 73.5% (England 78.8%), may reflect recall backlogs rather than lower clinical need.
Cancer register and children's immunisation
Cancer recorded prevalence is 5.2% (2,754 patients; England 3.8%). In Q1 2025/26, childhood coverage trailed the 95.0% target: 6-in-1 at 12 months was 87.3% and MMR1 at 24 months was 88.3%. At age 5, MMR1 was 96.3% but MMR2 trailed by 5.2 pp at 91.1% across 135 children, while 4-in-1 was 86.7%, consistent with unverified pre-school recall gaps.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers (7,482 of 13,490) in NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, against 55.3% in England, remaining below the 75.0% national ambition by 2028 by 19.5 pp. Staging completeness was 72.8% (13,490 of 18,522 registered cases). Between 2013 and 2022, early-stage diagnosis increased by +2.6 pp across the ICB, requiring about 2,640 additional early diagnoses annually to achieve the ambition. System performance reflects wider ICB delivery rather than PCN delivery. Primary care screening records show PCN breast screening at 74.2% and cervical screening at 71.9%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, Manchester University NHS Foundation Trust achieved 80.1% on the 28-day faster diagnosis standard (East Cheshire NHS Trust 81.1%, Stockport NHS Foundation Trust 83.2%, ICB 77.2%, England 79.3%), exceeding the 75.0% standard. However, 62-day referral to treatment was 72.8%, falling below the 85.0% standard by 12.2 pp (East Cheshire NHS Trust 53.4%, Stockport NHS Foundation Trust 74.7%, ICB 76.2%, England 71.2%). Diagnostic 6+ week waits were 14.7% for CT (England 9.9%) and 11.7% for MRI (England 21.4%). Hospital waiting times reflect provider performance rather than PCN delivery.
| Pathways within standard (%) | Manchester | East Cheshire | Stockport | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.06 | 81.08 | 83.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.54 | 96.30 | 97.39 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 72.85 | 53.41 | 74.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Manchester | East Cheshire | Stockport | England |
|---|---|---|---|---|
| MRI | 11.68 | 26.62 | 1.41 | 21.40 |
| CT | 14.66 | 11.49 | 2.93 | 9.92 |
| Echocardiography | 4.91 | 26.24 | 17.46 | 28.48 |
| Colonoscopy | 4.51 | 10.85 | 5.53 | 30.83 |
| Gastroscopy | 29.35 | 10.25 | 5.31 | 29.02 |
| All 15 DM01 tests | 8.98 | 16.17 | 14.08 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In June 2026, provisional Community Services Dataset records show that 60.8% of community contacts for Cheshire East residents (44,295 of 72,825 contacts) involved adults aged 65+. Borough activity reflects broader community provider activity rather than PCN delivery.
Practice variation and patient experience
Phone access varies by 36.1 pp and overall good experience by 18.2 pp
In 2025/26, overall QOF achievement ranged from 58.7% at David Lewis Medical Practice and 86.3% at Wilmslow Health Centre to 100.0% at Chelford Surgery against England's 92.5%. Vaccination and immunisation achievement varied by 100 pp, from 0.0% at David Lewis Medical Practice to 100.0% at Chelford Surgery (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Chelford Surgery | 117 | 0.0 | 85.5% | 75.8% | 99.4% |
| Alderley Edge | 111 | 0.0 | 91.1% | 79.5% | 97.8% |
| David Lewis | 10 | 0.0 | — | — | 97.2% |
| Handforth | 122 | 14.4 | 83.6% | 73.0% | 96.1% |
| Kenmore | 111 | 0.0 | 58.4% | 64.5% | 90.2% |
| Wilmslow | 84 | 3.2 | 55.0% | 61.7% | 81.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 tracked measures trailed England over three years, led by reviews
Between 2023 and 2025, 19 of 25 tracked measures trailed England's change. The widest lags were in routine annual reviews: asthma reviews fell 6.0% (England +4.4%), COPD reviews fell 5.2% (England +2.8%), and SMI blood pressure checks fell 3.4 pp (England +4.4 pp). Conversely, smoking cessation offers rose +1.4 pp to 98.1% (England +0.1 pp to 94.2%), and heart failure reviews reached 85.2% (England 78.5%). Recovering proactive annual recall across respiratory and mental health registers is the priority.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
BP check (SMI)
Alcohol record (psychosis)
BMI record (SMI)
Diabetes statin (CVD)
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 20 (1,247 beds) | n/a | Schools (catchment) | 50 | n/a |
| Children's centres | 1 | 14 | Places of worship | 55 | 272 |
| Libraries | 4 | 16 | Day centres (VCS) | 1 | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 11 | 41 | Primary academies | 11 | 78 |
| Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma reviews are 61.2% (England 65.7%; fell 6.0% over 2023 to 2025 vs England +4.4%), leaving 1,214 of 3,131 patients unreviewed; COPD reviews fell 5.2% to 75.0% across 663 patients. For discussion: run single-template respiratory recall with after-school and holiday slots, prioritising high-deprivation cohorts. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health check outreach
Across 398 SMI patients, blood pressure checks fell 3.4 pp over 2023 to 2025 to 78.0% (England +4.4 pp to 83.4%), alcohol recording is 71.9% (England 81.8%) and BMI is 76.8% (England 82.1%). For discussion: introduce single-visit physical health checks and raise shared-care coding reconciliation with mental health partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pre-school MMR2 and booster recall
In Q1 2025/26 across 135 five-year-olds, 4-in-1 coverage was 86.7% (below the 95.0% target by 8.3 pp) and MMR2 (91.1%) trailed MMR1 (96.3%) by 5.2 pp; 6-in-1 was 87.3% across 118 infants. For discussion: audit age-5 lists for children missing MMR2 or 4-in-1 boosters and offer catch-up clinics. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory frailty capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older adult blood pressure reviews (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood booster recall outreach (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Combined SMI physical health check outreach (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Pre-school MMR2 and booster recall (p12) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 · 6-in-1 coverage at 12 months · MMR dose 1 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
